Phase II Trial of Bortezomib and Bendamustine in the Treatment of Relapsed/Refractory Myeloma.
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 10 Jan 2018 Status changed to discontinued as PI left the institution before all data analysis was completed
- 31 Dec 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 16 Mar 2015 Planned End Date changed from 1 Feb 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.